

## Verquvo<sup>™</sup> (vericiguat) – New drug approval

- On January 20, 2021, Merck announced the FDA approval of Verquvo (vericiguat), to reduce the risk
  of cardiovascular (CV) death and heart failure (HF) hospitalization following a hospitalization for HF
  or need for outpatient intravenous diuretics, in adults with symptomatic chronic HF and ejection
  fraction less than 45%.
- Verquvo is a first-in-class stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. By directly stimulating sGC, vericiguat leads to smooth muscle relaxation and vasodilation.
- The efficacy of Verquvo was established in a randomized, placebo-controlled, double-blind, event-driven study (VICTORIA) in 5,050 adult patients with symptomatic chronic HF (New York Heart Association [NYHA] class II to IV) and left ventricular ejection fraction (LVEF) less than 45% following a worsening HF event. Patients were randomized to Verquvo or placebo. The primary endpoint was a composite of time to first event of CV death or hospitalization for HF. The median follow-up for the primary endpoint was 11 months.
  - Verquvo was superior to placebo in reducing the risk of CV death or HF hospitalization based on a time-to-event analysis (hazard ratio [HR]: 0.90, 95% CI: 0.82, 0.98; p = 0.019).
     Over the course of the study, the event rate (percentage of patients per year) was 33.6% with Verquvo vs. 37.8% with placebo.
- Verquvo carries a boxed warning for embryo-fetal toxicity.
- Verquvo is contraindicated in patients with concomitant use of other sGC stimulators and in pregnancy.
- The most common adverse reactions (≥ 5%) with Verguvo use were hypotension and anemia.
- The recommended starting dose of Verquvo is 2.5 mg orally once daily with food. The dose of Verquvo should be doubled approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.
- Merck's launch plans for Verquvo are pending. Verquvo will be available as a 2.5 mg, 5 mg, and 10 mg tablets.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.